Top

Published in:

Open Access 01-10-2014 | Transplantation (A Pileggi, Section Editor)

New Insight on Human Type 1 Diabetes Biology: nPOD and nPOD-Transplantation

Authors: Alberto Pugliese, Francesco Vendrame, Helena Reijonen, Mark A. Atkinson, Martha Campbell-Thompson, George W. Burke

Published in: Current Diabetes Reports | Issue 10/2014

Abstract

The Juvenile Diabetes Research Foundation (JDRF) Network for Pancreatic Organ Donors with Diabetes (JDRF nPOD) was established to obtain human pancreata and other tissues from organ donors with type 1 diabetes (T1D) in support of research focused on disease pathogenesis. Since 2007, nPOD has recovered tissues from over 100 T1D donors and distributed specimens to approximately 130 projects led by investigators worldwide. More recently, nPOD established a programmatic expansion that further links the transplantation world to nPOD, nPOD-Transplantation; this effort is pioneering novel approaches to extend the study of islet autoimmunity to the transplanted pancreas and to consent patients for postmortem organ donation directed towards diabetes research. Finally, nPOD actively fosters and coordinates collaborative research among nPOD investigators, with the formation of working groups and the application of team science approaches. Exciting findings are emerging from the collective work of nPOD investigators, which covers multiple aspects of islet autoimmunity and beta cell biology.

Pugliese A. The multiple origins of type 1 diabetes. Diabet Med. 2013;30(2):135–46.PubMedCrossRef

Herold KC, Vignali DA, Cooke A, Bluestone JA. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol. 2013;13(4):243–56.PubMedCrossRef

Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol. 2005;23:447–85.PubMedCrossRef

Pugliese A, Yang M, Kusmarteva I, Heiple T, Vendrame F, Wasserfall C, et al. The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings. Pediatr Diabetes. 2014;15(1):1–9.PubMedCrossRef

Campbell-Thompson M, Wasserfall C, Kaddis J, Albanese-O'Neill A, Staeva T, Nierras C, et al. Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab Res Rev. 2012;28(7):608–17.PubMedCrossRefPubMedCentral

Campbell-Thompson ML, Montgomery EL, Foss RM, Kolheffer KM, Phipps G, Schneider L, et al. Collection protocol for human pancreas. J Vis Exp. 2012;63:e4039.PubMed

Campbell-Thompson ML, Heiple T, Montgomery E, Zhang L, Schneider L. Staining protocols for human pancreatic islets. J Vis Exp. 2012;63:e4068.PubMed

Rewers A. Current concepts and controversies in prevention and treatment of diabetic ketoacidosis in children. Curr Diab Rep. 2012;12(5):524–32.PubMedCrossRef

Rosenbloom AL. The management of diabetic ketoacidosis in children. Diabetes Ther. 2010;1(2):103–20.PubMedCrossRefPubMedCentral

10.

Burke GW, III, Vendrame F, Pileggi A, Ciancio G, Reijonen H, and Pugliese A. Recurrence of autoimmunity following pancreas transplantation. CurrDiabRep. 2011.

11.

Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-Pagola A, Molano RD, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes. 2010;59(4):947–57.PubMedCrossRefPubMedCentral

12.

Sutherland DE, Goetz FC, Sibley RK. Recurrence of disease in pancreas transplants. Diabetes. 1989;38(Supplement 1):85–7.PubMedCrossRef

13.

Sibley RK, Sutherland DE. Pancreas transplantation. An immunohistologic and histopathologic examination of 100 grafts. Am J Pathol. 1987;128(1):151–70.PubMedPubMedCentral

14.

Sibley RK, Sutherland DE, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest. 1985;53(2):132–44.PubMed

15.

Sutherland DE, Sibley R, Xu XZ, Michael A, Srikanta AM, Taub F, et al. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Physicians. 1984;97:80–7.PubMed

16.

Diamantopoulos S, Allende G, Martin-Pagola A, Ciancio CR, Messinger S, Burke GW, et al. Recurrence of type 1 diabetes (T1DR) after simultaneous pancreas-kidney (SPK) transplantation is associated with islet cell autoantibody conversion. Acta Diabetol. 2007;44(S1):S13.

17.

Kitvarametha YYDS, Allende G, Vendrame F, Snowhite I, Sageshima J, Chen L, Ciancio G, Ruiz P, Reijonen H, Hutton J, Pugliese A, Burke GW. ZnT8 autoantibodies are associated with type 1 diabetes recurrence (T1DR) in simultaneous pancreas-kidney (SPK) transplant recipients. The Review of Diabetic Studies 2011;8(1).

18.

Laughlin E, Burke G, Pugliese A, Falk B, Nepom G. Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation. Clin Immunol. 2008;128(1):23–30.PubMedCrossRefPubMedCentral

19.

Martin-Pagola A, Sisino G, Allende G, Dominguez-Bendala J, Gianani R, Reijonen H, et al. Insulin protein and proliferation in ductal cells in the transplanted pancreas of patients with type 1 diabetes and recurrence of autoimmunity. Diabetologia. 2008;51(10):1803–13.PubMedCrossRefPubMedCentral

20.

Tanaka S, Kobayashi T, Nakanishi K, Okubo M, Murase T, Hashimoto M, et al. Evidence of primary beta-cell destruction by T-cells and beta-cell differentiation from pancreatic ductal cells in diabetes associated with active autoimmune chronic pancreatitis. Diabetes Care. 2001;24(9):1661–7.PubMedCrossRef

21.

Campbell-Thompson M, Dixon LR, Wasserfall C, Monroe M, McGuigan JM, Schatz D, et al. Pancreatic adenocarcinoma patients with localised chronic severe pancreatitis show an increased number of single beta-cells, without alterations in fractional insulin area. Diabetologia. 2009;52(2):262–70.PubMedCrossRef

22.

Bottino R, Criscimanna A, Casu A, He J, van der Windt DJ, Rudert WA, et al. Recovery of endogenous beta-cell function in nonhuman primates after chemical diabetes induction and islet transplantation. Diabetes. 2009;58(2):442–7.PubMedCrossRefPubMedCentral

23.

Wang GS, Rosenberg L, Scott FW. Tubular complexes as a source for islet neogenesis in the pancreas of diabetes-prone BB rats. Lab Invest. 2005;85(5):675–88.PubMedCrossRef

24.

Liu EH, Digon III BJ, Hirshberg B, Chang R, Wood BJ, Neeman Z, et al. Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft. Diabetologia. 2009;52(7):1369–80.PubMedCrossRefPubMedCentral

25.

Yip L, Su L, Sheng D, Chang P, Atkinson M, Czesak M, et al. Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes. NatImmunol. 2009;10(9):1026–33.

26.

Spencer J, Peakman M. Post-mortem analysis of islet pathology in type 1 diabetes illuminates the life and death of the beta cell. Clin Exp Immunol. 2009;155(2):125–7.PubMedCrossRefPubMedCentral

27.

Gianani R, Campbell-Thompson M, Sarkar SA, Wasserfall C, Pugliese A, Solis JM, et al. Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia. 2010;53(4):690–8.PubMedCrossRef

28.•

Keenan HA, Sun JK, Levine J, Doria A, Aiello LP, Eisenbarth G, et al. Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes. 2010;59(11):2846–53. Provided evidence for the presence of beta cell in the pancreata of T1D patients with long disease duration. PubMedCrossRefPubMedCentral

29.

Coppieters KT, Wiberg A, Amirian N, Kay TW, von Herrath MG. Persistent glucose transporter expression on pancreatic beta cells from longstanding type 1 diabetic individuals. Diabetes Metab Res Rev. 2011;27(8):746–54.PubMedCrossRef

30.

Green-Mitchell SM, Cazares LH, Semmes OJ, Nadler JL, Nyalwidhe JO. On-tissue identification of insulin: in situ reduction coupled with mass spectrometry imaging. Proteomics Clin Appl. 2011;5(7–8):448–53.PubMedCrossRefPubMedCentral

31.••

Coppieters KT, Dotta F, Amirian N, Campbell PD, Kay TW, Atkinson MA, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med. 2012;209(1):51–60. Demonstrated for the first time that autoreactive CD8 T cells are present in the insulitis lesion in the human pancreas, by using tetramers to demonstrate the antigen specificity of the infiltrating lymphocytes. PubMedCrossRefPubMedCentral

32.

Evanko SP, Potter-Perigo S, Bollyky PL, Nepom GT, Wight TN. Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration. Matrix Biol. 2012;31(2):90–100.PubMedCrossRefPubMedCentral

33.

Freeby M, Ichise M, Harris PE. Vesicular monoamine transporter, type 2 (vmat2) expression as it compares to insulin and pancreatic polypeptide in the head, body and tail of the human pancreas. Islets. 2012;4(6):393–7.PubMedCrossRefPubMedCentral

34.

Campbell-Thompson M, Wasserfall C, Montgomery EL, Atkinson MA, Kaddis JS. Pancreas organ weight in individuals with disease-associated autoantibodies at risk for type 1 diabetes. JAMA. 2012;308(22):2337–9.PubMedCrossRef

35.

Gregg BE, Moore PC, Demozay D, Hall BA, Li M, Husain A, et al. Formation of a human beta-cell population within pancreatic islets is set early in life. J Clin Endocrinol Metab. 2012;97(9):3197–206.PubMedCrossRefPubMedCentral

36.

Marhfour I, Lopez XM, Lefkaditis D, Salmon I, Allagnat F, Richardson SJ, et al. Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes. Diabetologia. 2012;55(9):2417–20.PubMedCrossRef

37.

Dai C, Brissova M, Hang Y, Thompson C, Poffenberger G, Shostak A, et al. Islet-enriched gene expression and glucose-induced insulin secretion in human and mouse islets. Diabetologia. 2012;55(3):707–18.PubMedCrossRefPubMedCentral

38.

Sarkar SA, Lee CE, Victorino F, Nguyen TT, Walters JA, Burrack A, et al. Expression and regulation of chemokines in murine and human type 1 diabetes. Diabetes. 2012;61(2):436–46.PubMedCrossRefPubMedCentral

39.•

Richardson SJ, Leete P, Bone AJ, Foulis AK, Morgan NG. Expression of the enteroviral capsid protein VP1 in the islet cells of patients with type 1 diabetes is associated with induction of protein kinase R and downregulation of Mcl-1. Diabetologia. 2013;56(1):185–93. Reported the presence of viral infection indicators in nPOD pancreata, including donors with long disease duration. This suggests that enteroviral infection of pancreatic beta cells may be chronic and persistent, or there may be multiple hits. PubMedCrossRef

40.

Taylor-Fishwick DA, Weaver JR, Grzesik W, Chakrabarti S, Green-Mitchell S, Imai Y, et al. Production and function of IL-12 in islets and beta cells. Diabetologia. 2013;56(1):126–35.PubMedCrossRefPubMedCentral

41.

Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62(7):2595–604.PubMedCrossRefPubMedCentral

42.•

Korpos E, Kadri N, Kappelhoff R, Wegner J, Overall CM, Weber E, et al. The peri-islet basement membrane, a barrier to infiltrating leukocytes in type 1 diabetes in mouse and human. Diabetes. 2013;62(2):531–42. Illustrated mechanisms by which infiltrating leukocytes penetrate islets, mechanisms that could be targeted by therapy. PubMedCrossRefPubMedCentral

43.

Yip L, Creusot RJ, Pager CT, Sarnow P, Fathman CG. Reduced DEAF1 function during type 1 diabetes inhibits translation in lymph node stromal cells by suppressing Eif4g3. J Mol Cell Biol. 2013;5(2):99–110.PubMedCrossRefPubMedCentral

44.•

Chen J, Feigenbaum L, Awasthi P, Butcher DO, Anver MR, Golubeva YG, et al. Insulin-dependent diabetes induced by pancreatic beta cell expression of IL-15 and IL-15Ralpha. Proc Natl Acad Sci USA. 2013;110:13534–9.PubMedCrossRefPubMedCentral

45.

Rowe P, Wasserfall C, Croker B, Campbell-Thompson M, Pugliese A, Atkinson M, and Schatz D. Increased Complement Activation in Human Type 1 Diabetes Pancreata. Diabetes Care. 2013.

46.•

Gardner JM, Metzger TC, McMahon EJ, Au-Yeung BB, Krawisz AK, Lu W, et al. Extrathymic Aire-expressing cells are a distinct bone marrow-derived population that induce functional inactivation of CD4 T cells. Immunity. 2013;13:10. Advanced our knowledge of the origin and mechanism of action of cells that are important in peripheral self-tolerance, including for molecules targeted as autoantigens in T1D.

47.•

Bogdani M, Johnson PY, Potter-Perigo S, Nagy N, Day AJ, Bollyky PL, and Wight TN. Hyaluronan and hyaluronan binding proteins accumulate in both human type 1 diabetic islets and lymphoid tissues and associate with inflammatory cells in insulitis. Diabetes. 2014. Describes a role for hyaluronan in the inflammatory process that leads to T1D.

48.

Gianani R, Putnam A, Still T, Yu L, Miao D, Gill RG, et al. Initial results of screening of nondiabetic organ donors for expression of islet autoantibodies. J Clin Endocrinol Metab. 2006;91(5):1855–61.PubMedCrossRef

49.

In't Veld P, Lievens D, De Grijse J, Ling Z, Van der Auwera B, Pipeleers-Marichal M, et al. Screening for insulitis in adult autoantibody-positive organ donors. Diabetes. 2007;56(9):2400–4.PubMedCrossRef

50.

Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care. 2009;32(12):2269–74.PubMedCrossRefPubMedCentral

51.

In’t Veld P. Insulitis in human type 1 diabetes: the quest for an elusive lesion. Islets. 2011;3(4):131–8.PubMedCrossRefPubMedCentral

52.

Krogvold L, Edwin B, Buanes T, Ludvigsson J, Korsgren O, Hyoty H, Frisk G, Hanssen KF, and Dahl-Jorgensen K. Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study. Diabetologia. 2014.

53.••

Campbell-Thompson ML, Atkinson MA, Butler AE, Chapman NM, Frisk G, Gianani R, et al. The diagnosis of insulitis in human type 1 diabetes. Diabetologia. 2013;56(11):2541–3. Provides consensus guidelines for the diagnosis of human insulitis. PubMedCrossRef

54.

Foulis AK, Liddle CN, Farwuharson MA, Richmond JA, Weir RS. The histopathology of the pancreas in type I diabetes (insulin dependent) mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia. 1986;29:267–74.PubMedCrossRef

55.

Jaeger C, Brendel MD, Eckhard M, Bretzel RG. Islet autoantibodies as potential markers for disease recurrence in clinical islet transplantation. Exp Clin Endocrinol Diabetes. 2000;108(5):328–33.PubMedCrossRef

56.

Pugliese A, Zeller M, Fernandez Jr A, Zalcberg LJ, Bartlett RJ, Ricordi C, et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. NatGenet. 1997;15(3):293–7.

57.

Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet. 1997;15(3):289–92.PubMedCrossRef

58.

Durinovic-Bello I, Wu RP, Gersuk VH, Sanda S, Shilling HG, Nepom GT. Insulin gene VNTR genotype associates with frequency and phenotype of the autoimmune response to proinsulin. Genes Immun. 2010;11(2):188–93.PubMedCrossRefPubMedCentral

59.

Durinovic-Bello I, Jelinek E, Schlosser M, Eiermann T, Boehm BO, Karges W, et al. Class III alleles at the insulin VNTR polymorphism are associated with regulatory T-cell responses to proinsulin epitopes in HLA-DR4, DQ8 individuals. Diabetes. 2005;54 Suppl 2:S18–24.PubMedCrossRef

60.

Pugliese A, Brown D, Garza D, Murchison D, Zeller M, Redondo M, et al. Self-antigen-presenting cells expressing diabetes-associated autoantigens exist in both thymus and peripheral lymphoid organs. JClinInvest. 2001;107(5):555–64.

61.

Gotter J, Brors B, Hergenhahn M, Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med. 2004;199(2):155–66.PubMedCrossRefPubMedCentral

62.

Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002;298(5597):1395–401.PubMedCrossRef

63.

Pugliese A. Insulin: a critical autoantigen and potential therapeutic agent in type 1 diabetes. Expert Rev Clin Immunol. 2006;2(3):419–31.PubMedCrossRef

64.

Gardner JM, DeVoss JJ, Friedman RS, Wong DJ, Tan YX, Zhou X, et al. Deletional tolerance mediated by extrathymic Aire-expressing cells. Science. 2008;321(5890):843–7.PubMedCrossRefPubMedCentral

65.

Klinke DJ. Age-corrected beta cell mass following onset of type 1 diabetes mellitus correlates with plasma C-peptide in humans. PLoS One. 2011;6(11):e26873.PubMedCrossRefPubMedCentral

66.

Klinke DJ. Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS ONE. 2008;3(1):e1374.PubMedCrossRefPubMedCentral

67.•

Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes. 2012;61(8):2066–73. This is an important clinical study that documents changes in C-peptide secretion after diagnosis, showing that significant C-peptide levels persist for at least 2 years after onset in many patients. PubMedCrossRefPubMedCentral

68.•

Oram RA, Jones AG, Besser RE, Knight BA, Shields BM, Brown RJ, et al. The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia. 2014;57(1):187–91. Provides evidence for continuing c-peptide secretion, even if at low levels, in most patients even after many years from onset. PubMedCrossRefPubMedCentral

69.

Bollyky PL, Bogdani M, Bollyky JB, Hull RL, and Wight TN. The role of hyaluronan and the extracellular matrix in islet inflammation and immune regulation. CurrDiabRep. 2012.

Title: New Insight on Human Type 1 Diabetes Biology: nPOD and nPOD-Transplantation
Authors: Alberto Pugliese
Francesco Vendrame
Helena Reijonen
Mark A. Atkinson
Martha Campbell-Thompson
George W. Burke
Publication date: 01-10-2014
Publisher: Springer US
Published in: Current Diabetes Reports / Issue 10/2014
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-014-0530-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2014

The Epidemiology of Diabetes and Cancer

Getting a Technology-Based Diabetes Intervention Ready for Prime Time: a Review of Usability Testing Studies

Weight Loss and Physical Activity for Disease Prevention in Obese Older Adults: an Important Role for Lifestyle Management

Is There an Association Between Diabetic Neuropathy and Low Vitamin D Levels?

Neurocognitive Outcomes in Pediatric Diabetes: a Developmental Perspective

Executive Function, Adherence, and Glycemic Control in Adolescents with Type 1 Diabetes: a Literature Review

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials